CD274 and nonpapillary renal cell carcinoma: Currently, at least 13 drugs in 6 categories have been approved for metastatic ccRCC, including VEGFR, mTORC1, c-Met, FGFR inhibition, cytokines, and most recently anti PD-1/PD-L1 immune checkpoint inhibitors (ICIs) which has been a promising pillar of nowadays clinical treatment [4, 9].